Jumpcan Pharmaceutical cancels stock options, schedules investor briefing

Hubei Jumpcan Pharmaceutical Co., Ltd. has completed the cancellation of 171,800 stock options under its 2022 restricted stock and stock option incentive plan. This decision, approved by the Tenth Board of Directors on September 9, 2025, follows the departure of certain incentive recipients and the failure of others to meet performance targets. The company confirmed that this cancellation will not impact its share capital structure or the ongoing implementation of the incentive plan.

In a related development, Hubei Jumpcan Pharmaceutical will host a semi-annual performance briefing on October 10, 2025, from 14:00 to 15:00. This online event, accessible via the Shanghai Stock Exchange Roadshow Center, aims to provide investors with a comprehensive overview of the company's performance and financial condition for the first half of 2025.

Investors can submit questions in advance from September 25 to October 9, 2025, and engage directly with management, including chairman Cao Longxiang and general manager Cao Fei, during the briefing. The company anticipates addressing common investor queries regarding its operating results and financial metrics.